TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33704046

Group type: EXPERIMENTAL
Intervention: Melatonin treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 32356470

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided quadratus lumborum block (QLB)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no QLB)
Number of subjects: 80
Study: 35392478

Group type: EXPERIMENTAL
Intervention: WeChat mini program-based intervention
Number of subjects: 158

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 158
Study: 33971625

Group type: EXPERIMENTAL
Intervention: Radiomics signature-based nomogram
Number of subjects: 105

Group type: COMPARATOR
Intervention: Traditional morphological features
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Combined radiomics signature and traditional morphological features
Number of subjects: 105
Study: 36033731

Group type: EXPERIMENTAL
Intervention: Nomogram to predict ICU prolonged LOS
Number of subjects: 14483
Study: 32454161

Group type: EXPERIMENTAL
Intervention: Methylphenidate (60 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 34533832

Group type: EXPERIMENTAL
Intervention: 1% metformin gel plus platelet-rich fibrin (PRF)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Platelet-rich fibrin (PRF) alone
Number of subjects: 21
Study: 33543637

Group type: EXPERIMENTAL
Intervention: Medication review with follow-up
Number of subjects: 291
Study: 616768438

Group type: EXPERIMENTAL
Intervention: Clopidogrel 600 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 34407385

Group type: EXPERIMENTAL
Intervention: Individualized CA-guided CPP targets
Number of subjects: 60

Group type: COMPARATOR
Intervention: Brain Trauma Foundation (BTF) guideline CPP target range
Number of subjects: 60
Study: 36422517

Group type: EXPERIMENTAL
Intervention: Hatha yoga intervention (8 weekly online classes)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Advice-only control group
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Hatha yoga intervention
Number of subjects: 79
Study: 33407868

Group type: EXPERIMENTAL
Intervention: Metronomic chemotherapy
Number of subjects: 81

Group type: COMPARATOR
Intervention: Palliative treatment
Number of subjects: 81
Study: 32062052

Group type: EXPERIMENTAL
Intervention: Welcome-IdA case conference model
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: Welcome-Neo case conference model
Number of subjects: 465

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: IdA cohort staff
Number of subjects: 465
Study: 33297841

Group type: EXPERIMENTAL
Intervention: Oral glucose (15g) + glycerol (9.45g)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Oral glucose (15g)
Number of subjects: 23
Study: 32768361

Group type: EXPERIMENTAL
Intervention: Netarsudil 0.02%/latanoprost 0.005% FDC
Number of subjects: 718

Group type: COMPARATOR
Intervention: Netarsudil 0.02% only
Number of subjects: 718

Group type: COMPARATOR
Intervention: Latanoprost 0.005% only
Number of subjects: 718
Study: 32726003

Group type: EXPERIMENTAL
Intervention: Huoxiang Zhengqi Oral Liquid and Jinhao Jiere Granules
Number of subjects: 22065

Group type: COMPARATOR
Intervention: Health guidance only (non-intervention group)
Number of subjects: 22065
Study: 34761713

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 2375

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2375
Study: 32999317

Group type: EXPERIMENTAL
Intervention: Variable-stiffness prosthetic foot set to randomized stiffness
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Communication between amputee subjects and one prosthetist subject to arrive at a mutually preferred stiffness
Number of subjects: 7
Study: 35385504

Group type: EXPERIMENTAL
Intervention: Triangular warning label (TL)
Number of subjects: 1384

Group type: COMPARATOR
Intervention: Rectangular 'high in' label with magnifying glass (ML)
Number of subjects: 1384
Study: 33370633

Group type: EXPERIMENTAL
Intervention: PNS + ASA
Number of subjects: 42

Group type: COMPARATOR
Intervention: ASA
Number of subjects: 42
Study: 34487395

Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR-NTX)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Buprenorphine-naloxone (BP-NLX)
Number of subjects: 143
Study: 32445429

Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 36494114

Group type: EXPERIMENTAL
Intervention: Mouthwash and dentifrice containing antimicrobial phthalocyanine derivative (APD)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Non-APD (control)
Number of subjects: 134
Study: 33581920

Group type: EXPERIMENTAL
Intervention: QVLP (30 μg HA/strain) from three sequential lots
Number of subjects: 1200
Study: 33109654

Group type: EXPERIMENTAL
Intervention: Active referral combined with a financial incentive (HK$300)
Number of subjects: 1134
Study: 36044391

Group type: EXPERIMENTAL
Intervention: Tranexamic Acid (TXA)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study: 34898447

Group type: EXPERIMENTAL
Intervention: PCC combined with usual care
Number of subjects: 222

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 222
Study: 34461886

Group type: EXPERIMENTAL
Intervention: Subcuticular continuous suture with Monocryl®
Number of subjects: 63

Group type: COMPARATOR
Intervention: Traditional suture with MonoNylon®
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Barbed suture with Stratafix®
Number of subjects: 63
Study: 33372300

Group type: EXPERIMENTAL
Intervention: Chronic rhinosinusitis (CRS) patients with prolonged viral shedding
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (sex-matched without prolonged viral shedding)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids usage in CRS patients
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Atopy in CRS patients
Number of subjects: 54
Study: 32384719

Group type: EXPERIMENTAL
Intervention: Pulse-based diet
Number of subjects: 27

Group type: COMPARATOR
Intervention: Regular diet
Number of subjects: 27
Study: 34058873

Group type: EXPERIMENTAL
Intervention: Early irrigation and debridement (I&D) within six hours of injury
Number of subjects: 2286

Group type: COMPARATOR
Intervention: Late irrigation and debridement (I&D) beyond six hours of injury
Number of subjects: 2286
Study: 33258553

Group type: EXPERIMENTAL
Intervention: Tofacitinib 11 mg XR daily
Number of subjects: 10
Study: 36427600

Group type: EXPERIMENTAL
Intervention: Levonorgestrel 52‐mg intrauterine device
Number of subjects: 655

Group type: COMPARATOR
Intervention: Copper T380A intrauterine device
Number of subjects: 655
Study: 32022640

Group type: EXPERIMENTAL
Intervention: Light regulation with light-emitting goggles in the morning and amber-lens glasses in the evening
Number of subjects: 26

Group type: COMPARATOR
Intervention: No light regulation
Number of subjects: 26
Study: 32065672

Group type: EXPERIMENTAL
Intervention: Diazepam nasal spray
Number of subjects: 48

Group type: COMPARATOR
Intervention: Diazepam rectal gel
Number of subjects: 48

Group type: COMPARATOR
Intervention: Oral diazepam
Number of subjects: 48
Study: 35222658

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate (intervention group)
Number of subjects: 52

Group type: COMPARATOR
Intervention: No magnesium supplementation (control group)
Number of subjects: 52
Study: 33207040

Group type: COMPARATOR
Intervention: Transient injury group (recovery ≤2 days)
Number of subjects: 2693

Group type: COMPARATOR
Intervention: Persistent injury group (recovery 3-7 days)
Number of subjects: 2693

Group type: COMPARATOR
Intervention: Acute kidney disease group (recovery ≥8 days)
Number of subjects: 2693

Group type: COMPARATOR
Intervention: Healthy control group (no AKI)
Number of subjects: 2693
Study: 35909263

Group type: EXPERIMENTAL
Intervention: 200 mg caffeine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 100 mg caffeine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (250 mg corn starch)
Number of subjects: 60
Study: 33580745

Group type: EXPERIMENTAL
Intervention: MR-OA (60/20 mg orlistat/mg acarbose)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: MR-OA (90/30 mg orlistat/mg acarbose)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: MR-OA (120/40 mg orlistat/mg acarbose)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Conventional orlistat (Xenical, 120 mg)
Number of subjects: 67
Study: 32193166

Group type: EXPERIMENTAL
Intervention: Fitspiration captions
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Body positive captions
Number of subjects: 109

Group type: COMPARATOR
Intervention: Neutral captions
Number of subjects: 109
Study: 35576279

Group type: EXPERIMENTAL
Intervention: Lipid-based nutritional supplement (LNS) (535 kcal)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo (92 kcal)
Number of subjects: 34
Study: 33421559

Group type: EXPERIMENTAL
Intervention: Intravenous TXA (2 g)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 35578688

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 70
Study: 34810365

Group type: EXPERIMENTAL
Intervention: Single implant mandibular overdentures (1IMO)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Two implant mandibular overdentures (2IMO)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Comparison between 1IMO and 2IMO
Number of subjects: 52
Study: 33860389

Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine (T-DM1)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Trastuzumab
Number of subjects: 101
Study: 32239968

Group type: EXPERIMENTAL
Intervention: Cow's milk-derived fortifier (CMDF)
Number of subjects: 114

Group type: COMPARATOR
Intervention: HM-derived fortifier (HMDF)
Number of subjects: 114
Study: 35971135

Group type: EXPERIMENTAL
Intervention: Office-GAP + Texting
Number of subjects: 17

Group type: COMPARATOR
Intervention: Texting only
Number of subjects: 17
Study: 33543897

Group type: COMPARATOR
Intervention: Oxytocin 5 units intravenous alone
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Oxytocin plus ergonovine 0.25 mg intravenous
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Oxytocin plus carboprost 0.25 mg intramuscular
Number of subjects: 102
Study: 34908146

Group type: EXPERIMENTAL
Intervention: Integrative Medical Group Visits (IMGV)
Number of subjects: 0
Study: 32738795

Group type: EXPERIMENTAL
Intervention: Expandable screws
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fenestrated screws augmented with polymethylmethacrylate
Number of subjects: 40
Study: 34561181

Group type: EXPERIMENTAL
Intervention: Continuous wound infusion (CWI) with ropivacaine 1% (1 mg kg–1 + 0.8 mg kg–1 hour–1)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Epidural administration of ropivacaine 0.5% (1.3 mg kg–1) and morphine (0.1 mg kg–1)
Number of subjects: 38
Study: 35609816

Group type: EXPERIMENTAL
Intervention: Intermittent theta burst stimulation (iTBS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 10 Hz high-frequency repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 60
Study: 33605002

Group type: EXPERIMENTAL
Intervention: Intralesional botulinum toxin type-A (BTX-A) injection
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intralesional platelet rich plasma (PRP) injection
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intralesional triamcinolone acetonide (TAC) injection
Number of subjects: 60
Study: 34690012

Group type: EXPERIMENTAL
Intervention: Text message intervention (reminder and informational texts); reminder texts once per day, informational texts three times per week for 45 days
Number of subjects: 101
Study: 34645365

Group type: EXPERIMENTAL
Intervention: Combined action observation and motor imagery training (AO+MI training)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Physical training
Number of subjects: 96
Study: 32360399

Group type: EXPERIMENTAL
Intervention: C-HIIT (supervised combined high-intensity interval training)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: C-MICT (supervised combined aerobic and resistance moderate-intensity continuous training)
Number of subjects: 32

Group type: COMPARATOR
Intervention: C-HIIT
Number of subjects: 32

Group type: COMPARATOR
Intervention: C-MICT
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: C-HIIT and C-MICT
Number of subjects: 32
Study: 35120640

Group type: EXPERIMENTAL
Intervention: Intermittent treatment (4-days-on and 3-days-off regimen)
Number of subjects: 636

Group type: COMPARATOR
Intervention: Continuous treatment (7-day regimen)
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: Intermittent treatment
Number of subjects: 636

Group type: COMPARATOR
Intervention: Continuous treatment
Number of subjects: 636
Study: 33790017

Group type: EXPERIMENTAL
Intervention: Deworming treatment (two to three additional years)
Number of subjects: 0
Study: 35404725

Group type: EXPERIMENTAL
Intervention: Active tDCS plus Matrix psychotherapy (n=15)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham tDCS plus Matrix psychotherapy (n=12)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Matrix psychotherapy only (n=13)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study: 34463288

Group type: EXPERIMENTAL
Intervention: KIO015
Number of subjects: 22

Group type: COMPARATOR
Intervention: HA-based device
Number of subjects: 22
Study: 32831212

Group type: EXPERIMENTAL
Intervention: Basketball-specific 8-week balance training group (BTG)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 31
Study: 35305341

Group type: EXPERIMENTAL
Intervention: avalglucosidase alfa
Number of subjects: 0

Group type: COMPARATOR
Intervention: alglucosidase alfa
Number of subjects: 0
Study: 33876436

Group type: EXPERIMENTAL
Intervention: SMAQ-12 (12-item short-form self-management ability questionnaire)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Exploratory Factor Analysis (EFA) and Confirmatory Factor Analysis (CFA)
Number of subjects: 480
Study: 33275544

Group type: EXPERIMENTAL
Intervention: Alcohol drink calibrated to reach approximately .050%, .075%, or .100% blood alcohol concentration
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo drink condition
Number of subjects: 210
Study: 35939083

Group type: EXPERIMENTAL
Intervention: Psilocybin-assisted therapy (n = 27)
Number of subjects: 1226

Group type: COMPARATOR
Intervention: Escitalopram (n = 25)
Number of subjects: 1226

Group type: EXPERIMENTAL
Intervention: Psychedelic experience (general)
Number of subjects: 1226
Study: 34331678

Group type: EXPERIMENTAL
Intervention: Daridorexant 50 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Daridorexant 200 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 32267056

Group type: EXPERIMENTAL
Intervention: Residual mitral regurgitation (rMR) ≤ 1+ at discharge (n = 251)
Number of subjects: 458

Group type: COMPARATOR
Intervention: Residual mitral regurgitation (rMR) 2+ at discharge (n = 173)
Number of subjects: 458

Group type: COMPARATOR
Intervention: Residual mitral regurgitation (rMR) ≥ 3+ at discharge (n = 34)
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: Stable rMR ≤ 1+ grades within 12 months
Number of subjects: 458
Study: 35664502

Group type: EXPERIMENTAL
Intervention: ReSET intervention (3 face-to-face sessions and telephone coaching)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 32744034

Group type: EXPERIMENTAL
Intervention: RBX Chinese herbal tablets (CHT)
Number of subjects: 165

Group type: COMPARATOR
Intervention: RBX Chinese formula granules (CFG)
Number of subjects: 165
Study: 36038439

Group type: EXPERIMENTAL
Intervention: Video Laryngoscope (VL) group (n = 186)
Number of subjects: 363

Group type: COMPARATOR
Intervention: Conventional group (C group; n = 177)
Number of subjects: 363
Study: 33436442

Group type: EXPERIMENTAL
Intervention: Non-steroidal anti-inflammatory drugs, continuous thoracic epidural analgesia, subcostal transversus abdominis plane (TAP) blocks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acetaminophen and non-steroidal anti-inflammatory drugs combined with thoracic epidural analgesia or bilateral oblique subcostal TAP blocks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systemic opioids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous dexmedetomidine, intravenous magnesium, intrathecal morphine, quadratus lumborum blocks, paravertebral nerve blocks, continuous local anesthetic wound infiltration, postoperative interpleural local anesthesia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine, ketamine, dexamethasone, gabapentinoids
Number of subjects: 0
Study: 36039038

Group type: EXPERIMENTAL
Intervention: Cefepime-MIP
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Cefepime Sandoz
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Linezolid Kabi
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Piperacillin Kabi
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Piperacillin Aurobindo
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Tazobactam Kabi
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Tazobactam Aurobindo
Number of subjects: 36
Study: 33894832

Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (0.8 mA, 100 μs, 30 Hz stimulation pulses, lasting 0.5 s) paired with rehabilitation (6 weeks of in-clinic therapy, three times per week, followed by home exercise programme)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation paired with rehabilitation
Number of subjects: 108

Group type: COMPARATOR
Intervention: Sham stimulation paired with rehabilitation (0 mA pulses)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Sham stimulation paired with rehabilitation
Number of subjects: 108
Study: 35754192

Group type: EXPERIMENTAL
Intervention: Red meat consumption intervention
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Red meat metabolite score
Number of subjects: 12
Study: 33840631

Group type: EXPERIMENTAL
Intervention: Increased FV intake by 3 or more servings
Number of subjects: 1165

Group type: COMPARATOR
Intervention: No change or decrease in FV intake
Number of subjects: 1165
Study: 35930254

Group type: EXPERIMENTAL
Intervention: WHO STOPS intervention
Number of subjects: 1406

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1406
Study: 32929215

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 32448299

Group type: EXPERIMENTAL
Intervention: COMBIND intervention (integrated mHealth application with PMTCT educational videos, SMS alerts, personal empowerment and motivational interviewing training)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: COMBIND intervention (personal empowerment training with motivational interviewing skills)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: COMBIND intervention (mHealth application)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: COMBIND intervention (SMS appointment alerts)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: COMBIND intervention
Number of subjects: 30
Study: 35963261

Group type: EXPERIMENTAL
Intervention: Levetiracetam (intravenous 500 mg every 12 h for 6 weeks)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 50
Study: 34526092

Group type: EXPERIMENTAL
Intervention: Simple randomization
Number of subjects: 11832

Group type: EXPERIMENTAL
Intervention: Covariate-constrained randomization using 11 prognostic characteristics
Number of subjects: 11832

Group type: EXPERIMENTAL
Intervention: Covariate-constrained randomization using principal components from 29 baseline historical variables
Number of subjects: 11832
Study: 32601075

Group type: EXPERIMENTAL
Intervention: Carboplatin-Paclitaxel-Trastuzumab (T)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Carboplatin-Paclitaxel (Control)
Number of subjects: 61
Study: 36229710

Group type: EXPERIMENTAL
Intervention: Elacestrant (oral SERD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other oral SERDs
Number of subjects: 0

Group type: COMPARATOR
Intervention: SERMs or AIs
Number of subjects: 0
Study: 32244777

Group type: EXPERIMENTAL
Intervention: EMS intervention (electromyostimulation combined with exercises and music)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 25
Study: 35953430

Group type: EXPERIMENTAL
Intervention: Photochromic contact lens (ACUVUE® OASYS with Transitions™ Light Intelligent Technology™)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Non-photochromic control lens (ACUVUE® OASYS 2‐week with HYDRACLEAR® PLUS)
Number of subjects: 250
Study: 33413287

Group type: EXPERIMENTAL
Intervention: Vaccination practices among UMs
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: HPV vaccine awareness
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Access to vaccination information
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Adult vaccination
Number of subjects: 22
Study: 32180239

Group type: EXPERIMENTAL
Intervention: Active-training group (N = 20) trained on a 1- (low load) & 3-back (high load) WM task
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control-training group (N = 20) performed a 0-back WM task
Number of subjects: 40
Study: 615705753

Group type: EXPERIMENTAL
Intervention: ET‐EG (Explore Transplant@Home with educator-guided coaching)
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: ET‐PG (Explore Transplant@Home, video-based, patient-guided program)
Number of subjects: 561

Group type: COMPARATOR
Intervention: SOC (Standard of Care transplant education)
Number of subjects: 561
Study: 34740884

Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg (FIL200)
Number of subjects: 3691

Group type: EXPERIMENTAL
Intervention: Filgotinib 100 mg (FIL100)
Number of subjects: 3691

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 3691
Study: 34063409

Group type: EXPERIMENTAL
Intervention: Brahmi essence for 12 weeks
Number of subjects: 0
Study: 32762340

Group type: EXPERIMENTAL
Intervention: OM-89 immunotherapy (6 mg), once daily for 3 months
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo, once daily for 3 months
Number of subjects: 49